Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zadaxin for HIV-positive Patients with Immune Reconstitution Disorders
NCT04963712Phase 1Completed
- Start
- Sep 2021
- Primary completion
- Jul 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of thymosin alpha 1 in human immunodeficiency virus infection (HIV). Primary endpoints: Change in CD4+ T cell counts at 24 weeks and Change in CD4/CD8 ratio at 24 weeks. Started Sep 2021; status: completed.
02
Drugs
thymosin alpha 1
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04963712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04963712.